Evidence map›Paper›PMID 31616247›Full record

ArticleFrontiers in molecular neuroscience2019

TIMP-1 Attenuates the Development of Inflammatory Pain Through MMP-Dependent and Receptor-Mediated Cell Signaling Mechanisms.

Brittany E Knight, Nathan Kozlowski, Joshua Havelin, Tamara King, Stephen J Crocker, Erin E Young, Kyle M Baumbauer

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Brittany E KnightDepartment of Neuroscience, UConn Health, Farmington, CT, United States.
Nathan KozlowskiSchool of Nursing, University of Connecticut, Storrs, CT, United States.
Joshua HavelinCenter for Excellence in the Neurosciences, University of New England, Biddeford, ME, United States.
Tamara KingCenter for Excellence in the Neurosciences, University of New England, Biddeford, ME, United States.
Stephen J CrockerDepartment of Neuroscience, UConn Health, Farmington, CT, United States.
Erin E YoungSchool of Nursing, University of Connecticut, Storrs, CT, United States.
Kyle M BaumbauerSchool of Nursing, University of Connecticut, Storrs, CT, United States.
UConn Health · USUniversity of Connecticut · USUniversity of Maine · USUniversity of New England · US

Funding

Tissue resident macrophages in sensory ganglia: function and impact on nociceptionP20GM103643 · NIGMS · UNIVERSITY OF NEW ENGLAND · PI MENG, IAN D · 2012 to 2021
$20.9M
Targeting ASIC3 to disrupt nociceptor sensitization following spinal cord injuryR21NS104789 · NINDS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI BAUMBAUER, KYLE M · 2018 to 2019
$425k
The Functional Consequences of SCI on Cutaneous NociceptorsR03NS096454 · NINDS · UNIVERSITY OF CONNECTICUT STORRS · PI BAUMBAUER, KYLE M · 2016 to 2017
$156k
NIGMS NIH HHS P20 GM103643NINDS NIH HHS R03 NS096454NINDS NIH HHS R21 NS104789
6 · The paper itself

Abstract

Unresolved inflammation is a significant predictor for developing chronic pain, and targeting the mechanisms underlying inflammation offers opportunities for therapeutic intervention. During inflammation, matrix metalloproteinase (MMP) activity contributes to tissue remodeling and inflammatory signaling, and is regulated by tissue inhibitors of metalloproteinases (TIMPs). TIMP-1 and -2 have known roles in pain, but only in the context of MMP inhibition. However, TIMP-1 also has receptor-mediated cell signaling functions that are not well understood. Here, we examined how TIMP-1-dependent cell signaling impacts inflammatory hypersensitivity and ongoing pain. We found that hindpaw injection of complete Freund's adjuvant (CFA) increased cutaneous TIMP-1 expression that peaked prior to development of mechanical hypersensitivity, suggesting that TIMP-1 inhibits the development of inflammatory hypersensitivity. To examine this possibility, we injected TIMP-1 knockout (T1KO) mice with CFA and found that T1KO mice exhibited rapid onset thermal and mechanical hypersensitivity at the site of inflammation that was absent or attenuated in WT controls. We also found that T1KO mice exhibited hypersensitivity in adjacent tissues innervated by different sets of afferents, as well as skin contralateral to the site of inflammation. Replacement of recombinant murine (rm)TIMP-1 alleviated hypersensitivity when administered at the site and time of inflammation. Administration of either the MMP inhibiting N-terminal or the cell signaling C-terminal domains recapitulated the antinociceptive effect of full-length rmTIMP-1, suggesting that rmTIMP-1inhibits hypersensitivity through MMP inhibition and receptor-mediated cell signaling. We also found that hypersensitivity was not due to genotype-specific differences in MMP-9 activity or expression, nor to differences in cytokine expression. Administration of rmTIMP-1 prevented mechanical hypersensitivity and ongoing pain in WT mice, collectively suggesting a novel role for TIMP-1 in the attenuation of inflammatory pain.

Indexed as

conditioned place preferencematrix metalloproteinasemechanical hypersensitivityongoing painpainthermal hyperalgesia

Identifiers

PMID31616247
PMCPMC6764257
OpenAlexW2970537259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.